31 results about "Anticancer Antibiotics" patented technology

Disclosed is an anticancer slow release agent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer antibiotics are selected from Idarubicin, Valtaxin, Pirarubicin and Mitoxantrone, The anti-metabolite drugs are selected from Pemetrexed, Carmustine, Tegafur, Zalcitabine, Emtritabine, Galocitabine, Ibacitabine, Ancitabine, Decitabine, Flurocitabine, Enocitabine, Imidazoletabine, Capecittabine, Gemcitabine, Fludrarbine, Raltitrexed, Dexrazoxane, Cladribine, Nolatrexed and folic acid, The slow release auxiliary materials are selected from EVAc, Polifeprosan, sebacylic acid copolymer, lactic acid, the viscosity of the suspension adjuvant is 100-3000cp (at 25-30 deg C), and is selected from sodium carboxymethylcellulose. The slow release microspheres can also be prepared into slow release implanting agent for injection or placement in or around tumor.

The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.

Disclosed is an anticancer medicinal injection and its use, which comprises slow release microballoons including anticancer active constituents and slow release auxiliary materials and dissolvent, the anticancer active constituents being platinum-group compounds, anti-metabolism, anti-cancer drugs, anticancer antibiotics or topoisomerase inhibitor, the slow release auxiliary materials are selected from polylactic acid, polyglycolic acid and glycolic acid copolymer, which can slowly release the anti-cancer medicament onto tumor partially during the degradation and absorption process, thus the whole body toxicity reaction is reduced appreciably , and the effective medicinal concentration can be sustained to the tumor partially. The suspending agent is selected from sodium carboxymethylcellulose and mannitol. The injection can lower down the whole body toxicity reaction of the anti-cancer medicament, selectively increase the tumor local medicinal concentration, and improve the treatment effect of the non-operative treatment methods such as chemotherapy, medicament and radiation.

A slow-release anticancer injection contains the slow-release microspheres and solvent. Said slow-release microsphere contains the active anticancer component chosen from 6 Pt compounds including bicycloplatinum, etc and 2 synergists including anticancer antibiotic or antimetabolic medicine, and the slow-release auxiliary.

A slow-release anticancer injection contains the slow-release microspheres and solvent. Said slow-release microsphere contains the active anticancer component chosen from 6 Pt compounds including bicycloplatinum, etc and 2 synergists including anticancer antibiotic or antimetabolic medicine, and the slow-release auxiliary.

Disclosed is a slow release injection agent of anticancer composition containing platinum-group compounds and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the platinum-group compounds are selected from cisplatin, Carboplatin, Nedaplatin or Oxaliplatin, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or Temozolomide, and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

A slow-release anticancer injection contains the slow-release microspheres and solvent. Said slow-release microsphere contains the active anticancer component chosen from 6 Pt compounds including bicycloplatinum, etc and 3 cytotoxins including antimitotic medicine, anticancer antibiotic, or antimetabolic medicine, and the slow-release auxiliary.

A method for treating cancer includes administering to a subject in need of the treatment an anticancer agent composition that includes the following agents as active ingredients; a LAT1 inhibitor, and one or more agents selected from the group consisting of an alkylating agent, a platinum-based antineoplastic agent, an anti-metabolite, a topoisomerase inhibitor, an anti-microtubule polymerizing agent, a hormonal agent, an anti-microtubule depolymerizing agent, an anticancer antibiotic, and a molecular targeted agent.

Disclosed is an anticancer, which contains antimetabolics fluorouracil and the synergist thereof, and is a sustained-release injection. The anti-cancer combination is composed of sustained-release microspheres and solvent; wherein, the sustained-release microsphere contains effective anticancer ingredients and auxiliary material; the solvent is common solvent or special solvent which contains suspending agent. The viscosity of the suspending agent is 100cp-3000cp (20 DEG C-30 DEG C) and is selected from carboxymethyl cellulose; the antimetabolics is selected from methotrexate, fluorouracil, carmofur, tegafur, decitabine, capecitabine or gemcitabine; the synergist is tetrazine medicine or anticancer antibiotics; the auxiliary material is selected from p(LAEG-EOP), p(DAPG-EOP), or polyphosphate copolymer, or copolymer or mixture of polyphosphate, polylactic acid, polifeprosan, sebacic acid and PLGA; the anticancer combination also can be made into sustained-release implants which can be injected or implanted in tumor or the periphery of tumor with the effective medicine concentration maintained for more than 50 days; meanwhile, the systemic reaction of the medicine is obviously reduced; the treatment effects of the non-operative treatments such as chemotherapy or radiation treatment are selectively enhanced.

Disclosed is a slow release injection agent of anticancer composition containing nitrosourea drugs and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microspheres comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the nitrosourea drugs are selected from Carmustine, Nimustine or Fotemustine, the synergistic agent can be selected from tetrazine drugs such as Mitozolomide or temozolomide and / or anticancer antibiotics such as Adriamycin, Aclarubicin, Epirubicin, mitomycin or pidorubicin, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer or blend of polyphosphate ester with polylactic acid, Polifeprosan, sebacylic acid and PLGA. The anticancer composition can also be prepared into slow release implanting agent, for injection or placement in or around tumor with a period of effective concentration maintenance over 60 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

Disclosed is an anticancer combination which contains antimetabolics and the synergist thereof, and is a sustained-release injection. The anti-cancer combination is composed of sustained-release microspheres and solvent; wherein, the sustained-release microsphere contains effective anticancer ingredients and auxiliary material; the solvent is common solvent or special solvent which contains suspending agent. The viscosity of the suspending agent is 100cp-3000cp (20 DEG C-30 DEG C) and is selected from carboxymethyl cellulose; the antimetabolics is selected from methotrexate, fluorouracil, carmofur, tegafur, decitabine, capecitabine or gemcitabine; the synergist is tetrazine medicine or anticancer antibiotics; the auxiliary material is selected from p(LAEG-EOP), p(DAPG-EOP), or polyphosphate copolymer, or copolymer or mixture of polyphosphate, polylactic acid, polifeprosan, sebacic acid and PLGA; the anticancer combination also can be made into sustained-release implants which can be injected or implanted in tumor or the periphery of tumor with the effective medicine concentration maintained for more than 50 days; meanwhile, the systemic reaction of the medicine is obviously reduced; the treatment effects of the non-operative treatments such as chemotherapy or radiation treatment are selectively enhanced.

An anticancer in vivo implant applied locally is prepared from the anticancer nitrosourea-type medicine, the anticancer synergist chosen from bichloroethanamine-type alkylating agent, anticancer antibiotic, and hormone-type anticancer medicine, and the biocompatible and biodegradable high-molecular polymer as medicinal additive.

The present invention relates to an anticancer slow-released injection containing vasoinhibitor. It is formed from slow-released microsphere and solvent. The slow-released microsphere includes anticancer effective component and slow-released auxiliary material, the solvent is special solvent containing suspension adjuvant. The anticancer effective component is vasoinhibitor selected from gemfitine, elotine, pelitine, thalidomide, vascular inhibine, endothelium inhibine, smasni, awasdine, kanatine or panitoma, etc. and/or cytotoxin medicine selected from antimitotic medicine, anticancer antibiotic and/or antimetabolite medicine. The slow-released auxiliary material is selected from polylactic acid and its copolymer, monomethyl polyethylene glycol/polylactic acid copolymer, polyethylene glycol/polylactic acid copolymer. sebacic acid and its copolymer and EVAc, etc. The suspension adjuvant is selected from carboxymethyl cellulose sodium, etc. and its viscosity is 10 cp-3000 cp (20 deg.C-30 deg.C). The slow-released microsphere also can be made into slow-released, implant preparation.

Disclosed is an anticancer slow release antibiotic agent which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The anticancer active constituents include anticancer antibiotics and/or anticancer antibiotic synergistic agent, the anticancer antibiotic synergistic agent is selected from anti-taxone, alkyl agent and/or plant alkaloids, the slow release auxiliary materials are selected from Polifeprosan, di-aliphatic acid and sebacylic acid copolymer, poly(erucic aciddipolymer-sebacylic acid), poly(fumaric acid-sebacylic acid), ethylene-vinylacetate copolymer, the viscosity of the suspension adjuvant is 100-3000cp (at 25-30 deg C), and is selected from sodium carboxymethylcellulose. The slow release microspheres can also be prepared into slow release implanting agent for lowering down the whole body toxicity reaction of the anti-cancer medicament, selectively increasing the tumor local medicinal concentration, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

Disclosed is an anticancer slow release injection containing anticancer antibiotics and synergistic agents, which comprises slow release micro-balloons and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being specific dissolvent containing suspension adjuvant. The anticancer active constituents include anticancer antibiotics and/or anticancer antibiotic synergistic agent selected from enzyme inhibitor and/or tetrazine-group compounds, the slow release auxiliary materials are selected from the following or their combination: Polifeprosan, di-aliphatic acid and sebacylic acid copolymer, poly(erucic aciddipolymer-sebacylic acid) copolymer, poly(fumaric acid-sebacylic acid) copolymer, poly(lactic acid), polyglycolic acid and glycolic acid copolymer, ethylene-vinylacetate copolymer or their combination. The viscosity of the suspension adjuvant is 100-3000cp (at 25-30 deg C), and is selected from sodium carboxymethylcellulose. The slow release microspheres can also be prepared into slow release implanting agent for injection or placement in or around tumor with improved treating effects of chemotherapy.

The invention relates to an anti-cancer compound as a slow release injection which contains phosphoinositide 3-kinase restrainer and relative booster, formed by slow release micro ball and solvent. The slow release micro ball comprises the anti-cancer effective components and slow release findings, the solvent is a common solvent or a special solvent with suspending agent, while the viscosity of suspending agent is 100cp-3000cp (at 20-30Deg. C), selected from carboxymethyl cellulose, the anti-cancer effective component is phosphoinositide 3-kinase restrainer and/or the phosphoinositide 3-kinase restrainer booster selected from self-anti-cancer antibiotics and/or tetrazine drug, the slow release finding is selected from phosphate polyester as p (LAEG-EOP), p (DAPG-EOP), or the polyester or mixture of phosphate and polylactic acid, polyphenyl, 2-aliphatic acid, sebacic acid polyester, poly (erucic acid dimmer-sebacic acid) or poly (fumaric acid-sebacic acid). The anti-cancer compound can be made as slow release plant agent, to inject cancer or around cancer to hold the effective drug density for more than 40 days, while it can significantly reduce the general reaction of drug and selectively strengthen the effect of non-surgery treatments as chemotherapy or the like.

An anti-cancer combination containing an antimetabolic medicine and a potentiating agent is a sustained-release injection, which contains a sustained-release microsphere and a menstruum. The sustained-release microsphere contains anti-cancer effective components and sustained-release auxiliary materials; the menstruum is an ordinary menstruum or a special menstruum containing a suspending agent. The viscosity of the suspending agent is 100cp to 3000cp (at the temperature of 20 DEG to 30 DEG) and the suspending agent is selected from carboxymethylcellulose sodium, etc. The antimetabolic medicine is selected from methotrexate, fluorouracil, carmofur, Tegafur, decitabine, capecitabine or Gemcitabine; the potentiating agent is tetrazine medicine and/or anti-cancer antibiotics; the sustained-release auxiliary materials are selected from a polyphosphonate copolymer of p(LAEG-EOP), p(DAPG-EOP) or a copolymer or a mixture of polyphosphate and polylactic acid, polifeprosan, decanedioic acid or PLGA. The anti-cancer combination can also be made into a sustained-release implanting agent, which can be injected or placed in or around tumor to maintain the effective medicine density for more than 50 days. The anti-cancer combination can also obviously reduce the general reaction of the medicine and selectively enhance the curing effect of non-operational therapies such as radiotherapy and chemotherapy.

A slow-release anticancer injection contains the slow-release microspheres and solvent. Said slow-release microsphere contains the active anticancer component chosen from 13 vascula inhibitors including gefitinib, angiostatin, etc and 3 cytotoxins including antimitotic medicine, anticancer antibiotic, or antimetabolic medicine, and the slow-release auxiliary.

The present invention relates to an anti-cancer medicine composition containing angiogenesis inhibitor and its synergist. It is formed from microsphere and solvent, in which the slow-release microsphere includes anti-cancer effective component and slow-release auxiliary material, and the solvent is general one or special one containing suspension adjuvant. The suspension adjuvant is selected from carboxymethylcellulose sodium, etc. and its viscosity is 100 cp-3000 cp (at 20 deg.C-30 deg.C). The slow-release auxiliary material is selected from polyphosphate copolymer of p(LAEG-EOP) and p(DAPG-EOP), etc. or polyphosphate and polylactic acid, difatty acid and sebacic acid copolymer, poly (erucidic acid dimmer-sebacic acid) or poly (fumaric acid-sebacic acid) copolymer or mixture. The anti-cancer effective component includes angiogenesis inhibitor and/or its synergist selected from anti-cancer antibiotic and/or tetrazine medicine. Said anti-cancer medicine composition also can be made into slow-release implantation.

Disclosed is a slow release injection agent of anticancer composition containing taxone and synergistic agent, which comprises slow release microspheres and dissolvent, wherein the slow release microballoons comprise anti-cancer active constituents and slow release auxiliary materials, the dissolvent being conventional dissolvent or specific dissolvent containing suspension adjuvant. The viscosity of the suspension adjuvant is 100-3000cp (at 20-30 deg C), and is selected from sodium carboxymethylcellulose, the anticancer active constituents include taxone and/or taxone synergistic agent selected from anticancer antibiotics and/or tetrazine medicaments, the slow release auxiliary materials are selected from polyphosphate ester copolymers such as p(LAEG-EOP), p(DAPG-EOP), copolymer of polyphosphate ester with polylactic acid, Polifeprosan, di-aliphatic acid and sebacylic acid, copolymer or blend of poly(erucic aciddipolymer-sebacylic acid) or poly(fumaric acid-sebacylic acid). The anticancer composition can also be prepared into slow release implanting agent, for injection or placement in or around tumor with a period of effective concentration maintenance over 40 days, as well as the treatment effect of appreciably lowering general reaction of the drugs, and improving the treatment effect of the non-operative treatment methods such as chemotherapy.

A slow-releasing injection for preventing and treating solid tumor is composed of the slow-release microballs containing active anticancer component chosen from angiostatin, anticancer antibiotic and antimetabolitic medicine and slow-release auxiliary, and the special solvent containing suspending aid.